- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03465293
Influence of Mechanical Bowel Preparation on GI Microbiota
Does Mechanical Bowel Preparation Destabilise the Gut Microbiota and Provide a Window of Opportunity in Which to Influence the Re-establishing Microbiota in Diverticulosis?
The mechanical bowel preparation (BP) used to clean the colon prior to colonoscopy frequently results in a significant but temporary reduction in patient's symptoms for a number of bowel disorders including symptomatic uncomplicated diverticular disease. The cause of this improvement is unknown.
We hypothesise that changes to the gut microbial population (microbiota) are responsible for this improvement and that the repopulation of the GI tract with bacteria following colonoscopy results in a return of their normal symptoms. This pilot study will test this in a preliminary way by examining the stool, urine and blood of patients before and after bowel preparation to detect any destabilising effect that BP has on the gut microbiota and to what extent the microbiota repopulates at 3 months If the hypothesis is proven, this study will show that BP generates a 'window of opportunity' in which to influence the subsequent re-establishment of the microbiota. This is with the eventual aim of correcting potential dysbiosis and preventing the progression of symptomatic uncomplicated diverticular disease (SUDD).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The mechanical bowel preparation (BP) procedure, which directly precedes colonic endoscopy, results in a significant reduction in reported symptoms for several bowel disorders (eg irritable bowel syndrome (IBS )), but as yet, there is little research-based supporting evidence. This proposal will use a robust experimental design to explore both the composition of the microbiota, and importantly, its metabolic activity to assess interactions with human hosts following BP. The aim of this pilot study is to generate data demonstrating the destabilising effects of BP on both the composition and metabolic activity of the gut microbiota.
If the hypothesis is proven, this study will show that BP generates a 'window of opportunity' in which to influence the subsequent re-establishment of the microbiota. This is with the eventual aim of correcting dysbiosis and preventing the development of symptomatic uncomplicated diverticular disease in patients with diverticulosis.
Background Diverticular disease, characterised by weakness of the supporting connective tissue of the wall of the colon leading to the formation of diverticula1, is somewhat neglected and does not receive scientific attention that other inflammatory gut disorders have. Despite this condition affecting 50% of our aging population, approximately 1/5 of which will develop debilitating symptomatic uncomplicated diverticular disease (SUDD)2, there is a paucity of knowledge in this field.
The factors determining the transition from asymptomatic diverticulosis to SUDD are unclear. However, the gut microbiota has been implicated in a recent small-scale study which correlated diverticulosis with depletion of Clostridium cluster IV. Clostridium cluster IX, Fusobacterium and Lactobacillaceae, all of which can exert an anti-inflammatory effects. Patients who present with left-side non-specific abdominal pain and diarrhoea are assessed by colonic endoscopy. A small-scale study showed that this procedure also resulted in a significant reduction in Lactobacillaceae in the control population after 1 month (n=10).
BP is received 14 and 20 hours prior to colonoscopy and involves oral administration with a variety of stimulant laxatives (eg Moviprep - polyethylene glycol) resulting in severe diarrhoea and complete clearance of faecal matter from the bowel. It is likely that this BP is implicated in any reduction in reported symptoms as opposed to the endoscopic procedure itself, although putative underlying mechanisms have yet to be identified.
Hypothesis: Bowel preparation for endoscopy will destabilise the gut microbiota in patients with diverticulosis. Re-establishment of this microbiota follows an altered developmental trajectory resulting in sustained changes to the composition of the microbiota. Furthermore, these observed changes will have functional consequences as identified through altered metabolic interactions at the microbe-host interface.
Aims and objectives:
- Quantify sustained observational changes which occur within the functional groups of the gut microbiota following BP (HTP FISHflow technology).
- Functional consequences of such changes to host metabolism, host-microbe co-metabolism and short chain fatty acid production will be assessed (nuclear magnetic resonance spectroscopy and gas chromatography respectively).
- Statistical data integration techniques will identify links between the altered microbiota and metabolic profiles to begin to determine the mechanisms underlying the influence of the gut microbiota in diverticulosis .
- The outputs above will identify whether a 'window of opportunity' occurs following BP which could be exploited to rectify dysbiosis as a basis for a later larger-scale study.
Experimental design
In order to assess the effects of BP on the colonic microbiota in diverticulosis, post-menopausal women with mild non-specific left sided abdominal pain and diarrhoea, who have been referred to the colorectal unit at the Royal Berkshire Hospital , will be recruited by the applicants (KT, PC). Patients who have not received antibiotics in the previous 3 months will complete a questionnaire to assess gastrointestinal symptoms, which will be based on those used in our previous human Irritable Bowel Syndrome (IBS) trials. Urine will be collected at t=0 (before BP), t=2d (24h after BP), t=8d (1 week after BP) and t=3 months (when recalled to the hospital). Faeces will be collected at the same timepoints except t=2d, instead the first void following BP will be requested. Patients are sent oral BP by post or collect them from the endoscopy unit, and we will exploit this to deliver faecal sample pots. Samples will be provided either at the hospital and immediately frozen, or patients will be asked to freeze and bring with them to their appointment . Later samples (t-8d, t=3 months), will be kept frozen at home then collected by University of Reading staff once both samples have been collected. Upon collection, patients will be provided with the questionnaire (and self-addressed envelope) to allow comparison of their symptoms 2 weeks and 3 months post BP with those reported beforehand (t=0).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Marie Lewis, PhD
- Phone Number: 0118 378 8708
- Email: marie.lewis@reading.ac.uk
Study Contact Backup
- Name: Philip Conaghan, MA DM FRCS
- Email: philip.conaghan@royalberkshire.nhs.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Suspected symptomatic uncomplicated diverticular disease
- Requires colonoscopy for investigation of symptoms
Exclusion Criteria:
- Under 18yo
- Previous bowel resection
- Antibiotics use in the last 6 months
- Medical condition precluding colonoscopy
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
SUDD post-menopausal female
Post-menopausal women with non-specific left side pain and altered bowel habit who are having mechanical bowel preparation for a colonoscopy
|
Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composition of the colonic microbiota pre and post bowel preparation
Time Frame: 6 months
|
Quantify sustained observational changes which occur within the functional groups of the gut microbiota following BP (HTP FISHflow technology)
|
6 months
|
Activity of the microbiota pre and post bowel preparation
Time Frame: 6 months
|
Functional consequences of observed changes to host metabolism, host-microbe co-metabolism and short chain fatty acid production.
This will be assessed by NMR spectroscopy and gas chromatography respectively
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marie Lewis, PhD, Reading University
Publications and helpful links
General Publications
- Drago L, Toscano M, De Grandi R, Casini V, Pace F. Persisting changes of intestinal microbiota after bowel lavage and colonoscopy. Eur J Gastroenterol Hepatol. 2016 May;28(5):532-7. doi: 10.1097/MEG.0000000000000581.
- Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012 Sep 13;489(7415):220-30. doi: 10.1038/nature11550.
- Merrifield CA, Lewis MC, Claus SP, Pearce JT, Cloarec O, Duncker S, Heinzmann SS, Dumas ME, Kochhar S, Rezzi S, Mercenier A, Nicholson JK, Bailey M, Holmes E. Weaning diet induces sustained metabolic phenotype shift in the pig and influences host response to Bifidobacterium lactis NCC2818. Gut. 2013 Jun;62(6):842-51. doi: 10.1136/gutjnl-2011-301656. Epub 2012 Jun 3.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FNSML1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diverticulosis, Colonic
-
Dr. Falk Pharma GmbHCompletedColonic DiverticulosisGermany
-
Saint Joseph Mercy Health SystemCompletedRectal Cancer | Colon Cancer | Colonic DiverticulosisUnited States
-
Saint Joseph Mercy Health SystemUnknownRectal Cancer | Colon Cancer | Colonic DiverticulosisUnited States
-
Saint Joseph Mercy Health SystemUnknownRectal Cancer | Colon Cancer | Colonic DiverticulosisUnited States
-
Groupe Hospitalier de la Rochelle Ré AunisMedtronicCompleted
-
Emmaus Medical, Inc.Completed
-
Assaf-Harofeh Medical CenterCompletedDiverticulitis | Diverticulosis, Colonic | Abdominal AdhesionIsrael
-
Centre Hospitalier Universitaire de NīmesCompletedColonic Neoplasms | Diverticulosis, Colonic
-
University of Roma La SapienzaUnknownDiverticulosis, Colonic | Diverticular Disease of ColonItaly
-
Odense University HospitalEnrolling by invitationDiverticulitis, ColonicDenmark
Clinical Trials on Bacterial composition and activity after bowel preparation
-
National and Kapodistrian University of AthensUnknownColorectal Cancer | Surgical Site Infection | Bowel Cancer | AntibioticGreece
-
Assistance Publique - Hôpitaux de ParisCompletedPatients With Rectal CancerFrance
-
Beijing Friendship HospitalRecruitingAcute Lower Gastrointestinal BleedingChina
-
University Hospital TuebingenCompletedHeart Assist DeviceGermany
-
Hospital Infantil de Mexico Federico GomezUnknownColostomy | Surgical AnastomosisMexico
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...CompletedEndometriosis, RectumItaly
-
N.N. Petrov National Medical Research Center of...RecruitingRectal CancerRussian Federation
-
Halina M Zyczynski, MDCompletedPelvic Organ Prolapse | ProlapseUnited States
-
Helsinki University Central HospitalActive, not recruitingColorectal Neoplasms | Colorectal Cancer | Surgery--Complications | Surgical Site Infection | Colorectal Carcinoma | Rectal Adenocarcinoma | Rectum Neoplasm | Rectum CarcinomaFinland
-
Centre Hospitalier Universitaire de BesanconCompletedPatient With an Indication of Colonoscopy for Inflammatory Bowel DiseaseFrance